458 related articles for article (PubMed ID: 31735286)
41. [Characteristics of pancreatic ductal adenocarcinoma immune microenvironment and related immunotherapy strategies].
Yuan M; Abuduhaibaier S; Ren SQ; Zheng ZHENG; Yuan CH
Zhonghua Yi Xue Za Zhi; 2021 Mar; 101(12):831-835. PubMed ID: 33789362
[TBL] [Abstract][Full Text] [Related]
42. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
Ibrahim AM; Wang YH
World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
[TBL] [Abstract][Full Text] [Related]
43. Immune-based therapies in pancreatic and colorectal cancers and biomarkers of responsiveness.
Di Caro G; Castino GF; Bergomas F; Cortese N; Chiriva-Internati M; Grizzi F; Marchesi F
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1219-28. PubMed ID: 25222571
[TBL] [Abstract][Full Text] [Related]
44. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression.
Lu J; Liu X; Liao YP; Salazar F; Sun B; Jiang W; Chang CH; Jiang J; Wang X; Wu AM; Meng H; Nel AE
Nat Commun; 2017 Nov; 8(1):1811. PubMed ID: 29180759
[TBL] [Abstract][Full Text] [Related]
45. Immunotherapy for pancreatic cancer: A 2020 update.
Schizas D; Charalampakis N; Kole C; Economopoulou P; Koustas E; Gkotsis E; Ziogas D; Psyrri A; Karamouzis MV
Cancer Treat Rev; 2020 Jun; 86():102016. PubMed ID: 32247999
[TBL] [Abstract][Full Text] [Related]
46. The microbiome and cancer for clinicians.
Picardo SL; Coburn B; Hansen AR
Crit Rev Oncol Hematol; 2019 Sep; 141():1-12. PubMed ID: 31202124
[TBL] [Abstract][Full Text] [Related]
47. Dilemma and Challenge of Immunotherapy for Pancreatic Cancer.
Wu J; Cai J
Dig Dis Sci; 2021 Feb; 66(2):359-368. PubMed ID: 32140943
[TBL] [Abstract][Full Text] [Related]
48. Myeloid-derived suppressor cells and their role in pancreatic cancer.
Pergamo M; Miller G
Cancer Gene Ther; 2017 Mar; 24(3):100-105. PubMed ID: 27910857
[TBL] [Abstract][Full Text] [Related]
49. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
50. Genetics and Biology of Pancreatic Ductal Adenocarcinoma.
Dunne RF; Hezel AF
Hematol Oncol Clin North Am; 2015 Aug; 29(4):595-608. PubMed ID: 26226899
[TBL] [Abstract][Full Text] [Related]
51. Delivering a Double Whammy: Targeting Stroma to Improve Immunotherapy Outcomes in Pancreatic Ductal Adenocarcinoma.
Lavania S
Gastroenterology; 2022 Nov; 163(5):1159-1161. PubMed ID: 36067817
[No Abstract] [Full Text] [Related]
52. The potential of gut microbiome as a non-invasive predictive biomarker for early detection of pancreatic cancer and hepatocellular carcinoma.
Kaźmierczak-Siedlecka K; Stachowska E; Folwarski M; Przewłócka K; Makarewicz W; Bryl E
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7275-7284. PubMed ID: 34919227
[TBL] [Abstract][Full Text] [Related]
53. Immunotherapy of pancreatic cancer.
Sunami Y; Kleeff J
Prog Mol Biol Transl Sci; 2019; 164():189-216. PubMed ID: 31383405
[TBL] [Abstract][Full Text] [Related]
54. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
55. Complex Role of Microbiome in Pancreatic Tumorigenesis: Potential Therapeutic Implications.
Amara S; Yang LV; Tiriveedhi V; Muzaffar M
Cells; 2022 Jun; 11(12):. PubMed ID: 35741028
[TBL] [Abstract][Full Text] [Related]
56. The Gut Microbiome and Pancreatic Cancer Development and Treatment.
Attebury H; Daley D
Cancer J; 2023 Mar-Apr 01; 29(2):49-56. PubMed ID: 36957973
[TBL] [Abstract][Full Text] [Related]
57. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
58. Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment.
Zhou W; Zhou Y; Chen X; Ning T; Chen H; Guo Q; Zhang Y; Liu P; Zhang Y; Li C; Chu Y; Sun T; Jiang C
Biomaterials; 2021 Jan; 268():120546. PubMed ID: 33253966
[TBL] [Abstract][Full Text] [Related]
59. Gut microbiome and cancer immunotherapy.
Li W; Deng Y; Chu Q; Zhang P
Cancer Lett; 2019 Apr; 447():41-47. PubMed ID: 30684593
[TBL] [Abstract][Full Text] [Related]
60. Immunological combination treatment holds the key to improving survival in pancreatic cancer.
Sodergren MH; Mangal N; Wasan H; Sadanandam A; Balachandran VP; Jiao LR; Habib N
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2897-2911. PubMed ID: 32748119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
